Document is current
Any future updates will be listed below
-
Authors
Andraka-Christou, Barbara https://orcid.org/0000-0001-6307-6369
Page, Cory
Schoebel, Victoria https://orcid.org/0000-0001-9211-6120
Buche, Jessica https://orcid.org/0000-0002-1726-047X
Haffajee, Rebecca L. https://orcid.org/0000-0003-0123-1516
-
Funding
Funding for this research was provided by:
Health Resources and Services Administration
- License Information
-
More Information
Article History
Received: 3 November 2021
Accepted: 11 July 2022
First Online: 9 August 2022
Declarations
:
: We received ethical approval from the University of Michigan Institutional Review Board for this research and respondents were provided with an explanation of research at the beginning of the survey.
: Not applicable.
: In 2017, Dr. Andraka-Christou received a research grant from Alkermes, the manufacturer of extended-release naltrexone, to develop educational online modules and a mobile application for college students with substance use disorder. None of the authors has relevant financial interests or relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, this submitted work. This article was conceived and drafted when Dr. Haffajee was employed at the RAND Corporation and the University of Michigan, and the findings and views in this article do not necessarily reflect the official views or policy of her current employer, the U.S. Department of Health and Human Services, or the U.S. Government.
